Cyclacel Pharmaceuticals

CYCC52

High Value

$0.35arrow_drop_up3.65%$0.01

High Value

Penny Stock

CYCC52

$0.35

arrow_drop_up3.65%$0.01

High Value

Penny Stock

Performance History

Key Stats
Open	$0.35
Prev. Close	$0.34
EPS	-27.40
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$2.23M
PE Ratio	-

	LOW	HIGH
Day Range	0.34	0.37
52 Week Range	0.33	11.40

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-27.40

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals Inc (CYCC) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel small molecule drugs for the treatment of cancer and other serious diseases. The company's lead product candidate is CYC065, an oral, second-generation cyclin-dependent kinase inhibitor that has shown promise in preclinical studies. CYC065 is being evaluated in multiple ongoing clinical trials, including Phase 1 and Phase 2 studies in patients with advanced solid tumors and hematological malignancies. The company also has a pipeline of other product candidates in various stages of development, targeting different pathways in cancer cells.

In terms of CYCC's stock price history, it has experienced fluctuations over the years. The stock price reached its highest point in the past 52 weeks at $5.78 and its lowest point at $1.25. Currently, the stock is trading within this range, showing moderate volatility. As for the market capitalization of CYCC, it is currently at $96.85 million, indicating the company's size in the market.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Spiro George Rombotis
Headquarters: Berkeley Heights
Employees: 0
Exchange: NASDAQ

add Cyclacel Pharmaceuticals to watchlist

Keep an eye on Cyclacel Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cyclacel Pharmaceuticals 's (CYCC) price per share?

The current price per share for Cyclacel Pharmaceuticals (CYCC) is $0.36. The stock has seen a price change of $0.01 recently, indicating a 3.66% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cyclacel Pharmaceuticals (CYCC)?

For Cyclacel Pharmaceuticals (CYCC), the 52-week high is $11.4, which is 3.1K% from the current price. The 52-week low is $0.33, the current price is 7.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cyclacel Pharmaceuticals (CYCC) a growth stock?

Cyclacel Pharmaceuticals (CYCC) has shown an average price growth of -4.13% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cyclacel Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cyclacel Pharmaceuticals (CYCC) stock price performance year to date (YTD)?

As of the latest data, Cyclacel Pharmaceuticals (CYCC) has a year-to-date price change of -86.57%. Over the past month, the stock has experienced a price change of -75.1%. Over the last three months, the change has been -70.33%. Over the past six months, the figure is -83.22%. Looking at a longer horizon, the five-year price change stands at -99.77%.

help

Is Cyclacel Pharmaceuticals (CYCC) a profitable company?

Cyclacel Pharmaceuticals (CYCC) has a net income of -$22.56M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.62% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -91.1K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 12.6%, providing insight into the company's sales performance and growth. The gross profit is $389K. Operating income is noted at -$25.45M. Furthermore, the EBITDA is -$20.18M.

help

What is the market capitalization of Cyclacel Pharmaceuticals (CYCC)?

Cyclacel Pharmaceuticals (CYCC) has a market capitalization of $2.24M. The average daily trading volume is 0.36, indicating the stock's liquidity and investor engagement.